Ketamine’s dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
The N-methyl-D-aspartate receptor antagonist ketamine has rapid onset activity in treatment-resistant depression, post-traumatic stress disorder and obsessive compulsive disorder. Due to similarities in brain network activity in depression and anxiety disorders, we hypothesized that ketamine might also be active in other refractory anxiety disorders. We evaluated the efficacy and safety of ketamine in 12 patients with refractory generalized anxiety disorder and/or social anxiety disorder who were not currently depressed, using an ascending single dose study design (0.25, 0.5, 1 mg/kg administered subcutaneously) at weekly intervals. Within 1 h of dosing, patients reported reduced anxiety, which persisted for up to seven days. A dose-response profile was noted for anxiolytic effects, dissociative side effects, and changes in blood pressure and heart rate, with minor changes at 0.25 mg/kg, and progressively greater and more durable changes at the higher doses. Ten of 12 patients were treatment responders at 0.5–1 mg/kg. Ketamine was safe and well tolerated in this population. Ketamine may be a potential therapeutic alternative for patients with refractory generalized anxiety disorder/social anxiety disorder. Along with its demonstrated effectiveness in patients with treatment-resistant depression, obsessive compulsive disorder and post-traumatic stress disorder, these data raise the intriguing possibility that ketamine may have broad efficacy in disorders characterized by negative emotional states, and that these disorders may share a common precipitating neurobiology.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Likewise, the neural, cognitive, information processing, and psychological patterns discussed above have broad transdiagnostic relevance, particularly with respect to other disorders of negative affect (e.g., anxiety, trauma-related conditions) 140 -that likewise respond to pharmacologic interventions with plasticity-enhancing properties 141,142 .”
From Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model (2020) · cites this paper as [142]
In the citing paper
“Furthermore, a 2017 study of 12 adults with generalized anxiety disorder and/or social anxiety found ketamine reduced anxiety symptoms; however, the study was open label and there was no placebo control (Glue et al, 2017).”
From Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial (2018) · cites this paper as Glue et al, 2017
In the citing paper
“Furthermore, a 2017 study of 12 adults with generalized anxiety disorder and/or social anxiety found ketamine reduced anxiety symptoms; however, the study was open label and there was no placebo control (Glue et al, 2017).”
From Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial (2018) · cites this paper as Glue et al, 2017
In the citing paper
“Ketamine was also shown to reduce anxiety symptoms in adults with treatment-refractory GAD (Glue et al., 2017) and with SAD, with reported increased social engagement on subsequent days (Taylor et al., 2018).”
From Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders (2019) · cites this paper as Glue et al., 2017
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders.
Widiger, T. A. (2000) · Encyclopedia of Psychology, Vol. 3. · doi:10.1037/10518-009 · Cited by 19,744
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection
Kroenke, K., Spitzer, R. L., Williams, J. B. W., Monahan, P. O., & Löwe, B. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-5-200703060-00004 · Cited by 4,741 · cited 3×
“Comorbidity of anxiety disorders is not uncommon in patients with treatment-resistant anxiety (Kroenke et al., 2007), and this cohort represents a real-world patient population.”
BackgroundAntidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
Liebowitz, M. R. (2015) · Modern Trends in Pharmacopsychiatry · doi:10.1159/000414022 · Cited by 2,266
Brief standard self-rating for phobic patients
Marks, I. M., & Mathews, A. M. (1979) · Behaviour Research and Therapy · doi:10.1016/0005-7967(79)90041-x · Cited by 1,801 · cited 1×
“Anxiety assessments included the Fear Questionnaire (FQ; score range 0–136; Marks and Mathews, 1979) and the HAM-A (range 0–52; Hamilton, 1959) predose, at 1, 2, 24, 72, and 168 h post-dose.”
MethodBandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Bremner, J. D., Krystal, J. H., Putnam, F. W., Southwick, S. M., Marmar, C., Charney, D. S., & Mazure, C. M. (1998) · Journal of Traumatic Stress · doi:10.1023/a:1024465317902 · Cited by 817 · cited 1×
“Tolerability assessments included reported adverse events throughout the study, and Clinician Administered Dissociative States Scale (CADSS; Bremner et al., 1998) predose, 30, and 60 min post-dose.”
MethodFeder, A., Parides, M. K., Murrough, J. W., Perez, A. M., Morgan, J. E., Saxena, S., Kirkwood, K., aan het Rot, M., Lapidus, K. A. B., Wan, L.-B., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.62 · Cited by 613
Cited by
Duman, R. S., Sanacora, G., & Krystal, J. H. (2019) · Neuron · doi:10.1016/j.neuron.2019.03.013 · Cited by 1,026
“This ketamine treatment regimen is also reported to produce rapid and sustained thereapeutic effects in a small trial (12 patients) of anxiety disorder (Glue et al., 2017).”
BackgroundNeuroplasticity in cognitive and psychological mechanisms of depression: an integrative model
Price, R. B., & Duman, R. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0615-x · Cited by 739
Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani, A., Murrough, J. W., Freire, R. C., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.595584 · Cited by 440
“A small open-label study suggested benefit of ketamine administered subcutaneously in a single ascending dose design in patients with refractory SAD and/or GAD (135).”
BackgroundSartori, S. B., & Singewald, N. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107402 · Cited by 236
Abdallah, C. G., Sanacora, G., Duman, R. S., & Krystal, J. H. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.05.010 · Cited by 219
Metadata
- Authors
- Glue, P., Medlicott, N. J., Harland, S., Neehoff, S., Anderson-Fahey, B., Le Nedelec, M., Gray, A., & McNaughton, N.
- Affiliations
- University of Otago (NZ)
- Department of Psychological Medicine, University of Otago, Dunedin, New Zealand
- Corresponding author
- Glue, Paul
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2017-04-26
- Volume
- 31
- Issue
- 10
- Pages
- 1302-1305
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2608289281
- Cited by
- 144
- References
- 19
- Citations by year
- 2026: 8 · 2025: 16 · 2024: 36 · 2023: 11 · 2022: 16 · 2021: 15 · 2020: 14 · 2019: 10 · 2018: 10 · 2017: 8
- FWCI
- 8.02
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- ketamine, generalized anxiety disorder, social anxiety disorder, NMDA receptor antagonists, dose-response relationship, anxiolytic effects, blood pressure and heart rate changes, rapid-acting antidepressants, safety and tolerability
- MeSH terms
- Adult, Antidepressive Agents, Anxiety, Anxiety Disorders, Depression, Depressive Disorder, Major, Major Depressive Disorder, Female, Humans, Ketamine, Male, Middle Aged, Obsessive-Compulsive Disorder, Stress Disorders, Post-Traumatic, Anti-Anxiety Agents, Receptors, N-Methyl-D-Aspartate, Young Adult, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ketamine’s dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders. https://app.cochat.ai/papers/10.1177/0269881117705089
- The paper
- Glue, P., Medlicott, N. J., Harland, S., Neehoff, S., Anderson-Fahey, B., Le Nedelec, M., Gray, A., & McNaughton, N. (2017). Ketamine’s dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders. Journal of Psychopharmacology. https://doi.org/10.1177/0269881117705089
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.